595 related articles for article (PubMed ID: 29768997)
21. Drug delivery approaches for the treatment of glioblastoma multiforme.
Fakhoury M
Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
[TBL] [Abstract][Full Text] [Related]
22. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
Wang D; Wang C; Wang L; Chen Y
Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
[TBL] [Abstract][Full Text] [Related]
23. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
24. The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy.
Mattei V; Santilli F; Martellucci S; Delle Monache S; Fabrizi J; Colapietro A; Angelucci A; Festuccia C
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917954
[TBL] [Abstract][Full Text] [Related]
25. Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment.
Zhao C; Zhu X; Tan J; Mei C; Cai X; Kong F
Biomed Pharmacother; 2024 Feb; 171():116113. PubMed ID: 38181717
[TBL] [Abstract][Full Text] [Related]
26. Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: A nanotechnological approach.
Agarwal S; Muniyandi P; Maekawa T; Kumar DS
Int J Pharm; 2018 Nov; 551(1-2):339-361. PubMed ID: 30236647
[TBL] [Abstract][Full Text] [Related]
27. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
28. Harnessing nanomedicine for therapeutic intervention in glioblastoma.
Gutkin A; Cohen ZR; Peer D
Expert Opin Drug Deliv; 2016 Nov; 13(11):1573-1582. PubMed ID: 27292970
[TBL] [Abstract][Full Text] [Related]
29. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
Kim JS; Shin DH; Kim JS
J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
[TBL] [Abstract][Full Text] [Related]
30. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence.
Auffinger B; Spencer D; Pytel P; Ahmed AU; Lesniak MS
Expert Rev Neurother; 2015; 15(7):741-52. PubMed ID: 26027432
[TBL] [Abstract][Full Text] [Related]
31. Current Challenges and Opportunities in Treating Glioblastoma.
Shergalis A; Bankhead A; Luesakul U; Muangsin N; Neamati N
Pharmacol Rev; 2018 Jul; 70(3):412-445. PubMed ID: 29669750
[TBL] [Abstract][Full Text] [Related]
32. Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update.
Hsu JF; Chu SM; Liao CC; Wang CJ; Wang YS; Lai MY; Wang HC; Huang HR; Tsai MH
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430494
[TBL] [Abstract][Full Text] [Related]
33. Systematic Evaluation of Transferrin-Modified Porous Silicon Nanoparticles for Targeted Delivery of Doxorubicin to Glioblastoma.
Luo M; Lewik G; Ratcliffe JC; Choi CHJ; Mäkilä E; Tong WY; Voelcker NH
ACS Appl Mater Interfaces; 2019 Sep; 11(37):33637-33649. PubMed ID: 31433156
[TBL] [Abstract][Full Text] [Related]
34. Brain-targeted Nano-architectures for Efficient Drug Delivery and Sensitization in Glioblastoma.
Ravuluri JAV; Rao V; Kumar G; Manandhar S; Cheruku SP; Bisht P; Chamallmudi MR; Nandakumar K; Kumar L; Kumar N
Curr Pharm Des; 2023; 29(22):1775-1790. PubMed ID: 37403389
[TBL] [Abstract][Full Text] [Related]
35. Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme.
Jena L; McErlean E; McCarthy H
Drug Deliv Transl Res; 2020 Apr; 10(2):304-318. PubMed ID: 31728942
[TBL] [Abstract][Full Text] [Related]
36.
Gallego L; Ceña V
Expert Opin Drug Deliv; 2020 Nov; 17(11):1541-1554. PubMed ID: 32791861
[TBL] [Abstract][Full Text] [Related]
37. Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches.
Miranda A; Blanco-Prieto M; Sousa J; Pais A; Vitorino C
Int J Pharm; 2017 Oct; 531(1):372-388. PubMed ID: 28755993
[TBL] [Abstract][Full Text] [Related]
38. Glioblastoma cancer stem cell biology: Potential theranostic targets.
Sharifzad F; Ghavami S; Verdi J; Mardpour S; Mollapour Sisakht M; Azizi Z; Taghikhani A; Łos MJ; Fakharian E; Ebrahimi M; Hamidieh AA
Drug Resist Updat; 2019 Jan; 42():35-45. PubMed ID: 30877905
[TBL] [Abstract][Full Text] [Related]
39. Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies.
Balça-Silva J; Matias D; Carmo AD; Sarmento-Ribeiro AB; Lopes MC; Moura-Neto V
Semin Cancer Biol; 2019 Oct; 58():130-141. PubMed ID: 30266571
[TBL] [Abstract][Full Text] [Related]
40. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
Reddy RG; Bhat UA; Chakravarty S; Kumar A
Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
